セラスの空売り残高が浮動株の33%に達し、経営陣の契約が変更される
Sellas Life Sciences Group saw short interest in its stock climb to a record 33% of the float as of June 15, according to Koyfin data, while the company amended executive severance agreements in an SEC filing on Thursday. The changes allow CEO Angelos Stergiou to receive eligible severance payments as a lump sum rather than installments, while CFO John Burns and Chief Development Officer Dragan Cicic signed new agreements providing 15 months of base salary, full target annual bonus, and accelera
SLS-14.38%
LucasBennett·06-26 10:57
